Newly listed stock has 27% upside potential! JM Financial issues buy call; Check target price and key triggers

What happened

JM Financial initiated coverage on Symbiotec Pharmalab, a pharmaceutical and biotechnology company listed in September, with a Buy rating and a target price of Rs.1,622 per share, implying around 27% upside from its previous closing price.

Confirmed

Global impact / market context

A Buy rating with a Rs.1,622 target signals that JM Financial expects Symbiotec's shares to rise about 27%. That view rests on new factory capacity starting production and on higher-profit businesses growing, which could lift earnings if contracts convert as expected.

Analyst inference

Symbiotec is newly listed, so analyst coverage can shape how investors view it. JM Financial points to steroid ingredient leadership and capacity nearing commercial use, offering a growth case that may attract investors comparing it with other pharmaceutical stocks.

Analyst inference

What to watch

1. About 61% of Symbiotec's gross capital expenditure block, meaning the total spent on long-term assets, is expected to enter commercialisation over the next six to 12 months, and contracts are already in place for most of this capacity. Confirmed
2. Watch whether the new capacity actually starts commercial production on schedule and whether signed contracts convert into revenue, since delays would weaken the earnings growth that supports JM Financial's target price. Analyst inference
3. Track growth in the higher-profit contract development and manufacturing organisation business and complex injectables, which JM Financial estimates will contribute around Rs.3.1 billion in EBITDA by FY29, a measure of operating profit. Proposed

Evidence

• Original source link unavailable